Neuphoria Therapeutics Inc. (NEUP)
(Delayed Data from NSDQ)
$7.79 USD
-0.31 (-3.83%)
Updated Aug 18, 2025 03:59 PM ET
After-Market: $7.79 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth D Momentum D VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
NEUP 7.79 -0.31(-3.83%)
Will NEUP be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for NEUP based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NEUP
Here's Why Momentum in Neuphoria Therapeutics Inc. (NEUP) Should Keep going
NEUP: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for NEUP
Neuphoria to Present at the American Society of Clinical Psychopharmacology (ASCP) 2025 Annual ...
Neuphoria Provides First Quarter 2025 Business Updates | NEUP Stock News